Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

You may be eligible if

• PROTOCOL ENTRY CRITERIA:
• -Disease Characteristics--
• Histologically confirmed stage III or IV melanoma 1 or more metastatic tumors for which surgery is not deemed to be a curative option
• Dacarbazine is indicated as first line chemotherapy
• At least 1 measurable tumor at least 1 cm2 but no greater than 100 cm2
• No history of brain metastases
• -Prior/Concurrent Therapy--
• Biologic therapy: At least 4 weeks since prior biologic therapy
• Chemotherapy: See Disease Characteristics; No prior chemotherapy
• Endocrine therapy: No concurrent immunosuppressive drugs
• Radiotherapy: At least 4 weeks since prior radiotherapy
• Surgery: At least 2 weeks since prior major surgery
• Other: No other concurrent anticancer drug therapy or experimental therapy
• -Patient Characteristics--
• Age: 18 and over
• Performance status: Karnofsky 80-100%
• Life expectancy: At least 24 weeks
• Hematopoietic: WBC at least 3,000/mm3; Platelet count at least 100,000/mm3; Hemoglobin at least 9 g/dL
• Hepatic: Bilirubin no greater than 2.0 mg/dL; SGOT/SGPT less than 3 times upper limit of normal (ULN); PT/PTT normal; Albumin normal; LDH no greater than 2 times ULN
• Renal: Creatinine no greater than 2.0 mg/dL
• Cardiovascular: No uncontrolled hypertension; No New York Heart Association class III or IV disease
• Other: HIV negative; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; No active autoimmune disease; No active infection requiring parenteral antibiotics; No uncontrolled diabetes mellitus; No other prior malignancy within the past 5 years except skin cancer or stage 0-II cervical cancer; No significant psychiatric disorders